All lobbying filings

TIBER CREEK GROUP

TIBER CREEK GROUP filed a Q3 report for ASTELLAS PHARMA US, INC. on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for ASTELLAS PHARMA US, INC. · Pharmacuetical company.

All filings by TIBER CREEK GROUP · Everything ASTELLAS PHARMA US, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Medicare/Medicaid

Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.